The STEP UP and SELECT trial data demonstrating efficacy and safety of high-dose semaglutide 2.4 mg (and the investigational 7.2 mg formulation) across diverse populations directly informs dose titration strategies and patient selection for family medicine practices managing obesity and metabolic disease. Understanding sex-specific treatment responses and tolerability patterns from these large randomized controlled trials enables clinicians to optimize GLP-1 therapy outcomes in women and identify populations most likely to achieve clinically meaningful weight loss and cardiometabolic benefit. These trial results provide the evidence base necessary to individualize GLP-1 prescribing decisions and manage patient expectations regarding efficacy stratification by demographic subgroup.
Novo Nordisk presented updated analyses from the STEP UP and SELECT trials examining semaglutide 7.2 mg at the European Congress on Obesity. STEP UP evaluated the highest approved dose of semaglutide in patients with obesity and cardiovascular disease, while SELECT examined the drug in patients with overweight or obesity and established cardiovascular disease. The presented data included analyses stratified by sex, providing insights into treatment efficacy and safety outcomes in women specifically compared to men receiving semaglutide at the 7.2 mg maintenance dose.
Key findings from the sex-stratified analyses demonstrated that women achieved weight loss and cardiometabolic improvements comparable to or in some measures exceeding those observed in men across both trials. Women participants showed sustained reductions in body weight, improvements in glycemic parameters where applicable, and favorable cardiovascular event outcomes. These sex-stratified results are clinically relevant as they address a historical gap in weight loss pharmacotherapy data specific to women and provide evidence that semaglutide efficacy is not substantially diminished in female patients with obesity and cardiovascular comorbidities.
For prescribers, these findings support the use of semaglutide 7.2 mg in women with obesity and cardiovascular disease, confirming that treatment decisions need not be modified based on patient sex. The data demonstrate that women respond adequately to the highest approved dose and experience similar risk reduction patterns as men in this patient population, providing evidence parity to support equitable access to and prescribing of high dose semaglutide across sexes in eligible patients.
Clinical Takeaway:
High-dose semaglutide (Wegovy 7.2 mg) demonstrates sustained weight loss and metabolic improvements in adults with obesity, with particular efficacy noted in women across the STEP UP and SELECT trials. The data supports GLP-1 receptor agonist therapy as an evidence-based intervention for weight management in primary care settings. When counseling patients, clarify that Wegovy is approved specifically for chronic weight management, distinct from its diabetes-specific formulation (Ozempic), to ensure appropriate expectations and insurance coverage discussion. Frame GLP-1 therapy within a comprehensive metabolic approach that includes lifestyle modification, as medication provides a physiologic tool to enhance dietary adherence and reduce hunger-driven eating patterns.
“What we’re seeing with the high-dose semaglutide data is particularly encouraging for women’s health outcomes, especially in the cardiovascular and metabolic domains where we’ve historically had gender-specific gaps in intervention efficacy. The SELECT trial data reinforces what I’m observing clinically: GLP-1 receptor agonists deliver robust benefits across diverse patient populations, not just those with diabetes. For my practice, this means I’m having more informed conversations with women about cardiovascular risk reduction as a primary indication for semaglutide, which shifts how we frame the discussion from weight loss alone to comprehensive cardiometabolic protection.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is Wegovy and how does it work?
Wegovy is a medication containing semaglutide that helps people manage their weight by affecting hormones in the brain that control hunger and fullness. It is given as a weekly injection and is prescribed for people with obesity or weight-related health conditions.
Who is eligible to take Wegovy?
Wegovy is typically prescribed for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who have weight-related health conditions like diabetes or heart disease. Your doctor will evaluate your individual health situation to determine if Wegovy is appropriate for you.
What dose of Wegovy was studied in the recent trials?
The recent data presented focused on the highest dose of Wegovy at 7.2 mg, which is given as a weekly injection. This dose was tested in clinical trials called STEP UP and SELECT to evaluate its safety and effectiveness.
Are there differences in how Wegovy works for women versus men?
Recent research suggests that women may experience certain health benefits from Wegovy, though the medication works through the same mechanism in all patients. Your doctor can discuss how Wegovy might specifically benefit your health goals.
What should I expect during the first few weeks of taking Wegovy?
Most patients start at a lower dose and gradually increase to the full dose over several weeks to allow their body to adjust. Common initial side effects may include mild nausea or changes in appetite, which often improve with time.
How much weight can I expect to lose with Wegovy?
Weight loss varies by individual, but clinical trials have shown significant weight reduction in many patients taking Wegovy. Your specific results will depend on your starting weight, overall health, diet, and exercise habits.
Is Wegovy a permanent solution for weight management?
Wegovy helps manage weight while you are taking it, but weight management typically requires ongoing use along with healthy eating and physical activity. Stopping the medication without lifestyle changes often results in weight regain over time.
What are the most common side effects of Wegovy?
The most frequently reported side effects include nausea, vomiting, diarrhea, and constipation, particularly when starting the medication. Most side effects tend to be mild and decrease as your body adjusts to the medication.
Can I take Wegovy if I have diabetes?
Wegovy can be used in patients with type 2 diabetes and may help improve blood sugar control in addition to supporting weight loss. You should inform your doctor about all your health conditions so they can monitor you appropriately.
How often do I need to see my doctor while taking Wegovy?
Your doctor will typically want to see you regularly to monitor your progress, check for side effects, and assess whether the medication is working well for you. The frequency of visits may vary depending on your individual health situation and how you respond to treatment.
